The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's Disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus
Zhao, C., Teng, E. M., Summers, R. G., Ming, G.-L., & Gage, F. H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3648-05.2006 · Cited by 1,257
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
Impaired Long-Term Potentiation, Spatial Learning, and Hippocampal Development in fyn Mutant Mice
Grant, S. G. N., O'Dell, T. J., Karl, K. A., Stein, P. L., Soriano, P., & Kandel, E. R. (1992) · Science · doi:10.1126/science.1361685 · Cited by 1,155
A Critical Period for Enhanced Synaptic Plasticity in Newly Generated Neurons of the Adult Brain
Ge, S., Yang, C.-H., Hsu, K.-S., Ming, G.-L., & Song, H. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.002 · Cited by 927
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Cited by
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Serotonin modulation of cortical neurons and networks
Celada, P., Puig, M. V., & Artigas, F. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00025 · Cited by 462
“Blockade of 5-HT6 receptors improves cortical performance in different learning and memory paradigms, an effect still poorly understood (Upton et al., 2008).”
BackgroundDrug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
“5-HT6 receptor antagonists are thought to enhance cholinergic neurotransmission [12].”
BackgroundNeurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease
Xu, Y., Yan, J., Zhou, P., Li, J., Gao, H., Xia, Y., & Wang, Q. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.02.002 · Cited by 301
The role of G protein-coupled receptors in the pathology of Alzheimer's disease
Thathiah, A., & De Strooper, B. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2977 · Cited by 288
The serotonergic system and cognitive function
Švob Štrac, D., Pivac, N., & Mück-Šeler, D. (2016) · Translational Neuroscience · doi:10.1515/tnsci-2016-0007 · Cited by 285
The serotonergic system in ageing and Alzheimer's disease
Rodríguez, J. J., Noristani, H. N., & Verkhratsky, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.010 · Cited by 264
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
A serotonergic axon-cilium synapse drives nuclear signaling to alter chromatin accessibility
Sheu, S.-H., Upadhyayula, S., Dupuy, V., Pang, S., Deng, F., Wan, J., Walpita, D., Pasolli, H. A., Houser, J., Sanchez-Martinez, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.07.026 · Cited by 162
“Since ligand stimulation is known to result in ciliary remodeling, including ciliary ectocy-tosis, decapitation, withdrawal, or shedding (Mirvis et al., 2019; Nager et al., 2017), a single snapshot in time may underestimate the frequency of axo-ciliary synapses.”
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace, T. L., Ballard, T. M., Pouzet, B., Riedel, W. J., & Wettstein, J. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.022 · Cited by 127
Role of Serotonin in Alzheimerʼs Disease: A New Therapeutic Target?
Geldenhuys, W. J., & Van der Schyf, C. J. (2011) · CNS Drugs · doi:10.2165/11590190-000000000-00000 · Cited by 117
Hu, L., Wang, B., & Zhang, Y. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0304-4 · Cited by 98
“Several studies have reported that 5-HT6 has great impact in cognition, especially in AD models [4].”
Więckowska, A., Kołaczkowski, M., Bucki, A., Godyń, J., Marcinkowska, M., Więckowski, K., Zaręba, P., Siwek, A., Kazek, G., Głuch-Lutwin, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.016 · Cited by 91
Acute EPA-induced learning and memory impairment in mice is prevented by DHA
Liu, J.-H., Wang, Q., You, Q.-L., Li, Z.-L., Hu, N.-Y., Wang, Y., Jin, Z.-L., Li, S.-J., Li, X.-W., Yang, J.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19255-1 · Cited by 77
Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., & Arnt, J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1702-5 · Cited by 74
Serotonin 6 receptor controls alzheimer’s disease and depression
Yun, H.-M., Park, K.-R., Kim, E.-C., Kim, S., & Hong, J. T. (2015) · Oncotarget · doi:10.18632/oncotarget.5777 · Cited by 62
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Wu, Y., Liu, Q., Qiu, Y., & Xie, L. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010367 · Cited by 34
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2195539 · Cited by 28
Astrocytic transporters in Alzheimer's disease
Ugbode, C., Hu, Y., Whalley, B., Peers, C., Rattray, M., & Dallas, M. L. (2017) · Biochemical Journal · doi:10.1042/bcj20160505 · Cited by 25
de Bruin, N. M. W. J., van Loevezijn, A., Wicke, K. M., de Haan, M., Venhorst, J., Lange, J. H. M., de Groote, L., van der Neut, M. A. W., Prickaerts, J., Andriambeloson, E., et al. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.06.020 · Cited by 22
“Based on these studies, Upton et al. (Upton et al., 2008) postulated that upon stimulation of the 5-HT6 receptor, GABA release is achieved, which in turn would cause inhibition of glutamatergic and cholinergic transmission.”
Method
Metadata
- Authors
- Upton, N., Chuang, T. T., Hunter, A. J., & Virley, D. J.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 5
- Issue
- 3
- Pages
- 458-469
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2039294854
- Cited by
- 255
- References
- 86
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.